Fractyl Health, Inc. (NASDAQ:GUTS) Stock Now Rated “Hold” by Sell-Side Brokerages

Fractyl Health, Inc. (NASDAQ:GUTS) has been given an average rating of “Hold” by the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $5.50.

Several brokerages have issued reports on GUTS. Weiss Ratings lowered Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Wall Street Zen downgraded Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Thursday, June 4th. Finally, Craig Hallum began coverage on Fractyl Health in a research report on Wednesday, July 1st. They set a “buy” rating and a $4.00 target price for the company.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Fractyl Health in the 2nd quarter valued at about $1,431,000. Pale Fire Capital SE increased its position in shares of Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after acquiring an additional 2,711,103 shares during the period. General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health during the second quarter valued at approximately $3,880,000. Atom Investors LP bought a new stake in shares of Fractyl Health during the fourth quarter valued at approximately $4,143,000. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Fractyl Health in the second quarter valued at approximately $8,968,058.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.47 on Friday. The firm has a market capitalization of $74.80 million, a PE ratio of -0.53 and a beta of 2.34. The stock’s fifty day moving average is $0.68 and its 200 day moving average is $0.68. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $2.44. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. On average, sell-side analysts anticipate that Fractyl Health will post -0.53 earnings per share for the current year.

Fractyl Health News Summary

Here are the key news stories impacting Fractyl Health this week:

• Neutral Sentiment: Fractyl shareholders approved a proposed reverse stock split at a September 24 special meeting. The action may help the company address Nasdaq listing requirements and improve its share price, but it does not change the company’s underlying financial or clinical outlook. Fractyl Health Stockholders Approve Reverse Stock Split Plan
• Neutral Sentiment: Analysts maintain a consensus “Hold” rating, reflecting caution around Fractyl’s development-stage business and uncertain prospects. Fractyl Health Given Consensus Hold Rating
• Neutral Sentiment: A market update reported zero shares sold short as of September 24, implying no measurable short-interest overhang; however, the report’s reference to a “large increase” in short interest is inconsistent with the zero-share figure.
• Negative Sentiment: Pomerantz announced that a securities class action has been filed against Fractyl Health and certain officers. The litigation adds potential legal costs, reputational damage and investor uncertainty. Pomerantz Class Action Announcement
• Negative Sentiment: Several firms announced or promoted related shareholder lawsuits covering investors who purchased GUTS securities between January 13, 2025, and January 29, 2026. The complaints allege that operational failures at one REMAIN-1 clinical site compromised weight-maintenance data and that Fractyl overstated the efficacy of its Revita DMR System. The allegations have not been proven, but the concentration of lawsuits is likely pressuring the shares. Investors seeking lead-plaintiff status generally face an October 20, 2026 deadline. Bronstein Gewirtz & Grossman Class Action Notice

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company is working to address the underlying biology of these conditions and pursue treatments that may provide more durable benefits than chronic dosing alone.

Fractyl Health’s technologies include the investigational Revita duodenal mucosal resurfacing (DMR) system, an endoscopic procedure designed to alter the lining of the duodenum and potentially improve metabolic control.